Q3 sales up for DiagnoCure but net loss widens
This article was originally published in Clinica
Cancer diagnostics specialist DiagnoCure saw sales of its noninvasive bladder cancer test, ImmunoCyt / uCyt+, jump 74% to around Can$111,750 ($104,140) for Q3 2008. However, revenue for the period was hurt by lower interest income, due to the use of funds to finance the company's operations and a reduction in interest from its investments. Turnover for the third quarter was down 13% to Can$486,070. Increase in cost of sales and R&D expenses and led to net loss nearly doubling to Can$4.2m for the period.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.